Accelerate to discover

Back to filter

Related topics

IncuCyte white paper: live-cell analysis for Neuroscientists

Sartorius

Mar 20, 2019

Stem cell technologies using iPSCs allow researchers to create differentiated neurons and support cells to study human...

Cell plasticity associated to circulating tumor cells from prostate cancer patients

Fluxion Biosciences

Mar 13, 2019

Treatment resistance is associated with tumor cells molecular plasticity. In metastatic castration resistant prostate...

Enhanced uptake of luminescent quantum dots by live cells

Etaluma

Mar 1, 2019

The steady progress made over the past threedecades in growing a variety of inorganic nanomaterials, with discreet...

Fat-water separation Imaging in Preclinical MRI

Bruker Biospin

Mar 1, 2019

Non-invasive in vivo phenotyping of adipose tissue deposits in small animal models is of great importance in...

Mar 21, 2019

Precision CellRad

Precision X-Ray

Feb 15, 2019

The CellRad system allows you to irradiate cells in your lab without compromising sterility or security. A smaller,...

New technique for dynamic monitoring of liquid tumor Cytotoxicity

Acea Biosciences

Feb 12, 2019

To develop and validate immuno-oncology therapies, scientists must understand the full dynamics of cytotoxic effectors...

Small animal 13C-hyperpolarized MRI

Bruker Biospin

Feb 8, 2019

13C-Hyperpolarized molecules provide a unique signature for molecular processes relevant to a range of disease...

Mar 21, 2019

Oncolytic chimeric orthopoxvirus causes regression of pancreatic cancer xenografts

Spectral Instruments Imaging

Jan 30, 2019

Pancreatic ductal adenocarcinoma has been increasing by 0.5% per year in the United States. This study describes the...

Show all topics (10)

Better antibody discovery using IntelliCyt’s iQue Screener

May 18, 2016

With the increasing need for new therapies for cancer, autoimmune disorders and Alzheimer’s disease, monoclonal antibodies are proving very successful due to their high affinity and specificity for their target antigens. In cancer, for example, their first use was as antagonists of oncogenic receptor tyrosine kinases, but today monoclonal antibodies have emerged as vehicles for the targeted delivery of potent chemotherapeutic agents and as powerful tools to manipulate anticancer immune responses. Currently,
more than 30 antibody therapeutics are marketed worldwide. Some analysts predict that, given the rate of current revenue growth and potential new approvals, the global market could reach $58 billion by 2016. In addition, there are hundreds of monoclonal antibody-based biologic drugs in various phases of clinical trials worldwide.

Read more

 

Scientific paper
Product news

Get more info

Riccardo Pasculli

Head of application support

Riccardo

Pasculli

+420 731 127 717

Send Message

Brand profile

IntelliCyt

IntelliCyt Corporation's high throughput flow technology is the first to enable screening suspension cells, beads, microbes and mixtures.

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey